Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world setting Gert-Jan Braunstahl 1 , Marco Deenstra 2 , Janice Canvin 3 , Guy Peachey 3 , Chien-Wei Chen 4 , Panayiotis Georgiou 3 , Robert Maykut 5* From EAACI International Severe Asthma Forum (ISAF 2012) Gothenburg, Sweden. 11-13 October 2012 Background With an estimated 300 million individuals affected worldwide, asthma is associated with substantial social and economic burden. The cost of treating uncontrolled severe allergic asthma (SAA) is high encompassing a variety of direct medical costs and indirect costs. We present data on real-world healthcare utilization (direct) and school/ work absence (indirect) in uncontrolled SAA patients receiving omalizumab in the eXpeRience registry.
Methods eXpeRience was a 2-year, global, single-arm, observational registry. Data were collected on real-world effectiveness, safety and use of omalizumab in patients with uncontrolled SAA. Asthma-related healthcare utilization (hospitalizations, emergency room visits or unscheduled doctor visits) and number of days missed from school/work were recorded.
Results
The intent-to-treat population comprised 916 (97.1%) patients. Compared with the pre-treatment period, there were reductions in healthcare utilization and school/ work absence after 12 and 24 months of omalizumab treatment. Unscheduled asthma-related doctor visits 3.8 (4.79); 823 0.7 (1.43); 684 0.4 (0.99); 619 Asthma-related medical healthcare uses* 6.2 (6.97); 811 1.0 (1.96); 684 0.5 (1.28); 618
Absence from work due to asthma # , days 26.4 (49.61); 347 3.5 (17.28); 295 1.0 (4.66); 296
Absence from school due to asthma # , days 20.7 (27.49); 57 1.6 (4.28); 59 1.9 (5.46); 58 
